PHOENIX, Ariz.– Humabiologics Inc., a regenerative medicine company founded by scientists and tissue industry experts, announced today it has successfully raised $1 million in seed funding.Continue reading
Author Archive: AZBio
RCT Acquires Translational Drug Development, LLC
Tucson, Ariz. & Scottsdale, Ariz. / June 4, 2020
Research Corporation Technologies, Inc. (RCT) announced today that it has acquired and invested growth capital into Translational Drug Development (TD2), the leading fully integrated precision oncology medicine development organization.
TD2 provides end-to-end solutions, including translational preclinical services; regulatory strategic guidance, planning and document submission services; and clinical trial design and execution for innovative oncology-focused companies.Continue reading
IMNA Announces New Appointment to Its Board Of Directors
IMNA Solutions announced today that it has appointed Russ Yelton, President/CEO of Yelton and Associates and Chairman of The Board of Trustees of AZAdvances to its board of directorsContinue reading
ASU develops state’s first saliva-based COVID-19 test
In an effort to make COVID-19 diagnostic testing easier and more readily available to Arizonans, researchers at Arizona State University have developed the state’s first saliva-based test.Continue reading
Kalos therapeutics announces important progress in therapeutic peptide for cancer program
Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer
Continue reading
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
- Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone
- Data Add to Body of Evidence from Prior Studies Demonstrating Benefit of Remdesivir in Hospitalized Patients with COVID-19
Lilly Begins World’s First Study of a Potential COVID-19 Antibody Treatment in Humans
“Lilly scientists delivered the first doses of our potential #COVID19 antibody treatment, flown to hospitals in several U.S. cities to start the world’s first human study of this kind of therapy to fight COVID infections.” @lillypad
- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera
- The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June
- Should Phase 1 results show the antibody can be safely administered, Lilly will initiate a Phase 2 proof of concept study to assess efficacy in vulnerable populationsContinue reading
UArizona Pharmacy Researcher Identifies Compounds That May Lead to Potential Treatments for COVID-19
Findings on compounds that block SARS-COV-2 viral replication may offer a promising starting point for further development of treatments to address the ongoing, devastating novel coronavirus pandemic.Continue reading
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are:
- Merck to acquire Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases, including COVID-19;
- IAVI and Merck collaborate to develop vaccine against COVID-19;
- Merck and Ridgeback Bio collaborate to advance development of an oral antiviral candidate for COVID-19, EIDD-2801.
Cost-effective cancer vaccine offers promise for prevention and treatment
In a new study appearing in the journal BMC Immunology, lead researcher Milene Peterson along with a team of researchers including Stephen Johnston, all in the Biodesign Center for Innovations in Medicine, took a look at the efficacy of personal vaccines versus shared vaccines, which target mutations shared by the majority of individuals with a cancer subtype.Continue reading